Definitive Contract 75N93020C00014
Award Date 6/1/20
Potential Completion Date 8/31/21
Potential Value $300K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Ames, IA 50014, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
- This federal contract award to Neovaxsyn Inc., a minority-owned small disadvantaged business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The $300,000 firm fixed-price contract supports the development of a next-generation immunoprevention platform against HIV-1, with a final completion date of October 31, 2025. The contract was awarded under the Small Business Innovation Research (SBIR) program, which...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,000,000.00 Small Business Innovation Research (SBIR) Phase II contract to Neovaxsyn Inc., a minority-owned, small disadvantaged business, to develop a nanovaccine for eliciting broadly neutralizing antibodies against HIV-1. The contract is a firm fixed price definitive contract with a completion date of June 30, 2027. Neovaxsyn Inc. has previously received federal funding from NIAID and the National Institute of...
- This is a $600,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to develop an effective human immunodeficiency virus (HIV) vaccine using engineered nanoparticles loaded with messenger RNA (mRNA) targeted to antigen presenting cells. This contract is part of the Small Business Innovation Research (SBIR)...
- This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
- This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
- This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to International AIDS Vaccine Initiative Inc. (IAVI), a non-profit organization. The $713,906.00 award supports the development of nanoparticle-based delivery systems for human immunodeficiency virus type 1 (HIV-1) biomolecules. The contract has a performance period ending on December 15, 2021 and utilizes a Cost...
- This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
- Neovaxsyn Inc., a minority-owned small disadvantaged business based in Ames, Iowa, was awarded a $300,000 Small Business Innovation Research (SBIR) Phase I contract by the National Institute of Allergy and Infectious Diseases (NIAID) on July 1, 2022. The contract, designated as a total small business set-aside, has an ultimate completion date of September 30, 2025 and is structured as a firm fixed-price definitive contract. The award originated from a pre-solicitation notice issued by the...
- This federal contract award, with a total ceiling value of $2,250,744.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization focused on HIV vaccine development. The purpose of the contract is to develop an optimized Phase 1 current Good Manufacturing Practice (cGMP) manufacturing process for lipid nanoparticle (LNP) fabrication that enables covalent coupling of an HIV-1 envelope...